Bafna Pharmaceuticals Ltd (BAFNAPH)
🎯 Key Takeaways
- Bafna Pharmaceuticals is transitioning from a historically loss-making entity to a profitable, strategically repositioning mid-cap player in the pharmaceutical sector, marked by strong net profit growth, regulatory recognition, and a shift toward global market expansion and ESG integration. The company has moved beyond operational instability seen in 2018-19 to demonstrate sustainable profitability and strategic momentum.
- Revenue grew 68.9% QoQ to ₹12 in Q2FY20.
- ⚠️ 1) Dependence on regulatory approvals for new dossiers in international markets introduces execution and timeline risk. 2) Margins, while improving, r
- Market Cap
- ₹859
- P/B Ratio
- -202.50
- Debt/Equity
- -0.71
- Promoter
- 75.0%
📖 The Story
Bafna Pharmaceuticals is transitioning from a historically loss-making entity to a profitable, strategically repositioning mid-cap player in the pharmaceutical sector, marked by strong net profit growth, regulatory recognition, and a shift toward global market expansion and ESG integration. The company has moved beyond operational instability seen in 2018-19 to demonstrate sustainable profitability and strategic momentum.
📰 What's Happening
Recent developments include the approval of unaudited Q1 FY27 results showing revenue of ₹2,658.32 lakhs and profit of ₹7.51 lakhs, the announcement of the 31st AGM on September 11, 2026 via video conference with record date September 4, and the completion of asset monetization of its Madhavaram manufacturing unit. The company also secured a credit rating upgrade to positive from ICRA, recognized as Emerging Company of the Year in Healthcare, and reduced promoter holding to 74.57% as part of equity streamlining. Management is targeting EBITDA margins of at least 15% and plans to file 6-8 new dossiers for regulated and emerging markets to expand its global footprint.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2018 | Jun 2019 | Sep 2019 |
|---|---|---|---|
| Revenue | 9 | 7 | 12 |
| Operating Profit | -1 | -4 | -1 |
| OPM % | -6.5% | -56.6% | -9.5% |
| Net Profit | -1 | -2 | -1 |
| EPS | ₹-0.80 | ₹-0.90 | ₹-0.25 |
The company has reversed its historical losses, with net profit surging 167% to ₹111 million in FY25-26 from prior periods of consistent losses in 2018-19, while revenue grew 3.26% YoY to ₹1,506.17 million. Quarterly trends show improving operational stability, with Q1 FY27 reporting ₹2,658.32 lakhs in revenue and ₹7.51 lakhs in profit, up from earlier loss-making quarters. This profitability inflection is attributed to cost optimization, margin improvement, and strategic investments in R&D and regulated markets, as highlighted in management commentary.
🔮 Management Outlook & What's Next
Management has articulated an ambitious outlook focused on scaling regulated market presence, filing 6-8 new dossiers, and achieving EBITDA margins of at least 15%. They emphasize sustainable value creation through R&D investments, green energy adoption (targeting 60% solar power), and ESG initiatives. The company is also prioritizing minimum-debt status and strategic expansion into regulated markets, signaling a long-term growth trajectory anchored in compliance, innovation, and operational efficiency.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2019 | Mar 2020 | Mar 2020 |
|---|---|---|---|
| Equity Capital | 24 | 2 | 24 |
| Reserves | -5 | -7 | -7 |
| Borrowings | 46 | 3 | 47 |
| Total Liabilities | 72 | 71 | 121 |
| Fixed Assets | 37 | 35 | 36 |
| Investments | 0 | 0 | 0 |
| Total Assets | 72 | 71 | 121 |
The balance sheet reflects a strengthening financial position with equity and reserves improving over time, while borrowings remain manageable and aligned with a minimum-debt strategy. The company has completed asset monetization, notably of its Madhavaram manufacturing unit, suggesting non-core asset optimization. Despite negative reserves in some periods, the overall capital structure supports growth initiatives without aggressive leverage, indicating prudent capital allocation focused on reinvestment and regulatory compliance rather than debt-funded expansion.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2020 |
|---|---|
| Operating | -34 |
| Investing | +33 |
| Financing | +7 |
| Net Cash Flow | +6 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 75.0% | 75.0% | 75.0% | 75.0% |
| FII | 9.3% | 9.3% | 9.3% | 9.3% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 12.0% | 12.1% | 12.1% | 12.0% |
| # Shareholders | 7,572 | 7,119 | 6,928 | 7,062 |
Promoter holding has been steadily reduced to 74.57% as part of equity streamlining, while institutional interest remains stable with FII holding at 9.34% over recent quarters and public shareholders increasing from 11.97% to 12.13%. The number of shareholders has grown from 6,928 to 7,572, indicating rising retail participation. There are no signs of significant FII or DII exits, and no promoter pledges are evident, suggesting confidence in the company’s trajectory from both promoter and institutional investors.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Dependence on regulatory approvals for new dossiers in international markets introduces execution and timeline risk. 2) Margins, while improving, remain sensitive to raw material costs and pricing pressures in competitive segments. 3) The company’s historical loss-making base and volatility in quarterly profits raise concerns about sustainability of earnings. 4) Limited DII participation and low public float (12.13%) could lead to share price volatility.
📋 Recent Filings
- Announcement2026-09-26Bafna Pharmaceuticals announced that its trading window will close on October 1, 2026, and remain shut until 48 hours after the un-audited quarterly r…
- 🟡 voting results2026-09-11Bafna Pharmaceuticals held its 31st AGM on September 11, 2026, where shareholders approved the adoption of audited financial statements for FY2026, th…
- 🟡 Board Meeting2026-09-11Bafna Pharmaceuticals held its 31st AGM on September 11, 2026 via video conference, adopting audited FY2026 financials, reappointing Director Upendar …
- 🔴 annual report2026-08-19Bafna Pharmaceuticals Limited announced its 31st Annual General Meeting (AGM) to be held on September 11, 2026, via Video Conferencing, and disclosed …
- 🟡 Board Meeting2026-08-13Bafna Pharmaceuticals announced its 31st Annual General Meeting will be held on September 11, 2026, via video conference, with book closure from Septe…
- 🟡 Board Meeting2026-08-13Bafna Pharmaceuticals announced its 31st Annual General Meeting will be held on September 11, 2026 via video conference, with book closure from Septem…
- 🟡 Board Meeting2026-08-11Bafna Pharmaceuticals announced the outcome of its August 11, 2026 board meeting, approving unaudited Q1 FY27 financial results, setting the 31st AGM …
- share transfer2026-07-09Bafna Pharmaceuticals Limited received a SEBI-mandated certificate from Cameo Corporate Services Limited confirming dematerialized securities for the …
- Financial Results2026-06-26Bafna Pharmaceuticals announced that its designated insiders and immediate relatives must remain in a trading window closure from July 1 to August 2, …
- 🟡 Board Meeting2026-06-22Bafna Pharmaceuticals announced the retirement of Independent Director Navin Kumar effective June 22, 2026, triggering board committee reshuffles. Mr.…
🧠 Analyst's Read
Bafna Pharmaceuticals is emerging as a fundamentally improving player with strong profitability momentum, strategic regulatory progress, and a clear growth roadmap. Investors should monitor the successful filing and commercialization of new dossiers in regulated markets and the pace of margin expansion toward the 15% EBITDA target, as these will be critical catalysts for sustained value creation.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when BAFNAPH files new disclosures
Track BAFNAPH filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track BAFNAPH — FreeFree account · 2 AI queries/day